药康生物
(688046)
| 流通市值：122.19亿 | | | 总市值：122.19亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 385,163,121.74 | 323,103,636.54 | 415,147,269.66 | 486,620,728.45 |
| 交易性金融资产 | 715,747,396.18 | 714,810,074.84 | 670,480,086.84 | 757,693,494.32 |
| 应收票据及应收账款 | 424,795,923.83 | 422,522,107.9 | 425,599,216.78 | 384,962,303.74 |
| 应收账款 | 424,795,923.83 | 422,522,107.9 | 425,599,216.78 | 384,962,303.74 |
| 预付款项 | 7,754,781.48 | 7,498,869.67 | 9,243,175.4 | 7,205,818.97 |
| 其他应收款合计 | 4,584,431.15 | 4,607,736.48 | 4,689,142.76 | 4,239,335.82 |
| 存货 | 104,046,781.47 | 95,877,933.32 | 86,840,183.99 | 72,961,120.3 |
| 一年内到期的非流动资产 | 31,539,945.15 | - | - | - |
| 其他流动资产 | 120,613,761.43 | 133,430,427.49 | 99,354,010.73 | 37,790,878.92 |
| 流动资产平衡项目 | -0.01 | 0 | 0.01 | 0 |
| 流动资产合计 | 1,794,246,142.42 | 1,701,850,786.24 | 1,711,353,086.17 | 1,751,473,680.52 |
| 非流动资产: | | | | |
| 长期股权投资 | 82,397,068.89 | 78,060,363.68 | 79,007,170.53 | 88,812,314.68 |
| 其他权益工具投资 | 14,530,836.5 | 14,530,836.5 | 10,794,420 | 10,794,420 |
| 其他非流动金融资产 | 10,186,986.33 | 10,123,972.62 | 10,061,643.84 | 10,000,000 |
| 固定资产 | 563,410,287.66 | 562,692,808.19 | 568,061,353.27 | 573,246,662.51 |
| 在建工程 | 32,411,585.2 | 29,460,464.16 | 24,767,345.38 | 22,460,943.33 |
| 生产性生物资产 | 7,639,906.93 | 7,563,236.76 | 7,018,983.74 | 7,333,557.34 |
| 使用权资产 | 74,703,308.87 | 79,925,425.12 | 85,285,329.73 | 90,683,728.51 |
| 无形资产 | 66,987,174.62 | 68,588,249.47 | 72,052,454.49 | 71,371,542.72 |
| 开发支出 | 3,754,291.56 | 3,754,291.56 | 3,754,291.56 | 3,754,291.56 |
| 长期待摊费用 | 20,633,166.24 | 21,797,499.8 | 23,173,557.84 | 24,723,086.04 |
| 递延所得税资产 | 33,467,452.5 | 32,304,469.72 | 33,474,709.04 | 33,138,894.25 |
| 其他非流动资产 | 201,554,087.89 | 228,426,757.28 | 239,233,784.34 | 177,273,690.01 |
| 非流动资产合计 | 1,111,676,153.19 | 1,137,228,374.86 | 1,156,685,043.76 | 1,113,593,130.95 |
| 资产总计 | 2,905,922,295.61 | 2,839,079,161.1 | 2,868,038,129.93 | 2,865,066,811.47 |
| 流动负债: | | | | |
| 短期借款 | 116,215,408.31 | 138,463,335.2 | 158,186,638.4 | 187,325,204.71 |
| 衍生金融负债 | 220,048.15 | 184,789.76 | - | - |
| 应付票据及应付账款 | 75,652,279.27 | 74,240,647.32 | 71,081,683.56 | 68,133,909.91 |
| 应付账款 | 75,652,279.27 | 74,240,647.32 | 71,081,683.56 | 68,133,909.91 |
| 合同负债 | 184,452,001.25 | 171,251,034.03 | 172,982,805.73 | 176,398,259 |
| 应付职工薪酬 | 45,732,378.87 | 40,268,748.2 | 29,106,972.99 | 52,523,918.63 |
| 应交税费 | 16,415,600.29 | 14,640,475.45 | 15,212,330.55 | 11,440,614.24 |
| 其他应付款合计 | 13,945,338.88 | 5,063,635.15 | 6,678,011.09 | 7,569,704.57 |
| 一年内到期的非流动负债 | 25,695,598.22 | 25,020,974.43 | 24,374,866.44 | 23,752,541.69 |
| 流动负债平衡项目 | 0 | 0 | -0.01 | 0 |
| 流动负债合计 | 478,328,653.24 | 469,133,639.54 | 477,623,308.75 | 527,144,152.75 |
| 非流动负债: | | | | |
| 租赁负债 | 66,702,629.91 | 70,120,037.45 | 76,951,952.29 | 80,234,045.76 |
| 递延收益 | 24,855,296.68 | 25,436,217.42 | 26,857,138.16 | 22,562,058.89 |
| 递延所得税负债 | 7,761,408.94 | 8,006,366.44 | 7,721,033.06 | 7,929,400.5 |
| 非流动负债合计 | 99,319,335.53 | 103,562,621.31 | 111,530,123.51 | 110,725,505.15 |
| 负债合计 | 577,647,988.77 | 572,696,260.85 | 589,153,432.26 | 637,869,657.9 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,186,200 | 410,000,000 | 410,000,000 | 410,000,000 |
| 资本公积 | 1,262,901,219.46 | 1,258,279,728.46 | 1,256,297,725.59 | 1,253,186,839.59 |
| 减:库存股 | 16,017,183.67 | 16,017,183.67 | 16,017,183.67 | 16,017,183.67 |
| 其他综合收益 | 5,838,430.23 | 8,055,327.23 | 8,545,424.93 | 7,072,562.75 |
| 盈余公积 | 62,310,381.53 | 62,310,381.53 | 62,310,381.53 | 62,310,381.53 |
| 未分配利润 | 603,055,259.29 | 543,754,646.7 | 557,748,349.29 | 510,644,553.37 |
| 归属于母公司股东权益合计 | 2,328,274,306.84 | 2,266,382,900.25 | 2,278,884,697.67 | 2,227,197,153.57 |
| 股东权益合计 | 2,328,274,306.84 | 2,266,382,900.25 | 2,278,884,697.67 | 2,227,197,153.57 |
| 负债和股东权益合计 | 2,905,922,295.61 | 2,839,079,161.1 | 2,868,038,129.93 | 2,865,066,811.47 |
| 公告日期 | 2026-10-29 | 2026-08-20 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |